Neuronetics, Inc. (NASDAQ: STIM) has established the first National TMS Therapy Awareness Day, which will be observed annually on May 14 during Mental Health Awareness Month. This initiative seeks to increase understanding of transcranial magnetic stimulation (TMS) as a viable non-drug treatment for major depressive disorder (MDD), anxiety-related depression, and obsessive-compulsive disorder (OCD).
As the leading provider of TMS therapy in the United States, NeuroStar received FDA clearance in 2024 to treat adolescents, expanding its services beyond adults. Currently, over 300 million individuals are covered by insurance plans that provide access to NeuroStar TMS therapy, including Medicare and Tricare.
On this inaugural awareness day, Neuronetics will highlight real patient experiences, including the story of Kristen Gingrich, a licensed clinical social worker who found relief from her long-standing depression through NeuroStar TMS treatment after unsuccessfully trying various antidepressants and talk therapy. Kristen’s story will be shared on social media platforms, showcasing the impact of TMS therapy and encouraging others facing similar challenges to seek help.
Keith Sullivan, President and CEO of Neuronetics, emphasized the importance of this awareness day: “National TMS Awareness Day aims to offer hope to those who have struggled with depression and have not found relief from medication. We want to ensure that everyone knows about effective non-drug treatments like NeuroStar TMS therapy.”
Transcranial magnetic stimulation therapy was first approved by the FDA in 2008 for adults with treatment-resistant depression. Since then, it has gained acceptance as an evidence-based option for individuals who have not responded adequately to traditional medication. NeuroStar is recognized for its precision technology, which delivers focused magnetic pulses to specific areas of the brain, making each treatment session both effective and consistent.
The 2025 American Psychiatric Association Annual Meeting will feature research data presented by NeuroStar, focusing on TMS protocols and their effectiveness. This research builds on previous studies to further validate the efficacy of TMS therapy for treating depression.
Neuronetics aims to continue its mission of improving mental health by making NeuroStar Advanced Therapy widely available. The company operates treatment centers across the United States, where it provides NeuroStar therapy for MDD and other mental health conditions. With over 7.4 million treatments administered and the largest clinical dataset for TMS therapy, NeuroStar remains at the forefront of mental health treatment.
As part of its commitment to patient care, NeuroStar also offers SPRAVATO® (esketamine) nasal spray for treatment-resistant depression, further broadening the options available for patients who struggle with depression.
For more information about National TMS Therapy Awareness Day and NeuroStar TMS therapy, visit TMSAwareness.com.
Russian 
English 
French 
German 
Spanish 
Belarusian 
Ukrainian